Who invested in CHARM Therapeutics?
CHARM Therapeutics's investors include General Catalyst, Khosla Ventures, nVentures, New Enterprise Associates and OrbiMed, and 1 more on record.

United Kingdom · Series B startup
Funding summaryUpdated 26 Oct 2026
$149Mraised across 5 rounds since 2022, from 5 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Source recordedSEC filing: $17M sold, first sale Aug 2025
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Source recordedSEC filing: $20M sold, first sale Apr 2023
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yetSEC filing: $37M sold, first sale Apr 2022
CHARM Therapeutics filed 4 raises, $69M in all. Filings say how much was sold and to how many investors; they never name the investors.
From CHARM Therapeutics's own website: 2 founders, 1 on the team.
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
CHARM Therapeutics's investors include General Catalyst, Khosla Ventures, nVentures, New Enterprise Associates and OrbiMed, and 1 more on record.
CHARM Therapeutics has raised $149M across 5 rounds since 2022.
CHARM Therapeutics's most recent round was a Series B of $80M in Sept 2025.
Its most recent round, $80M in Sept 2025, is also its largest on record.
CHARM Therapeutics's first round on record, in Apr 2023, was backed by General Catalyst, Khosla Ventures and OrbiMed and 1 others.
CHARM Therapeutics's latest named round is a Series B, in Sept 2025.
CHARM Therapeutics is based in the United Kingdom.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.